CAR-T cell immunotherapy has proven to be highly effective in the treatment of blood cancers. But how can that success be recreated in solid tumors? Roisin McGuigan, Editor, Immuno–Oncology Insights, speaks with John Maher, Scientific Founder and Chief Scientific Officer, Leucid Bio, about his work in developing innovative therapies for solid tumor applications, including the lateral CAR platform, which adopts a more natural configuration of CAR molecules.
